Oxaliplatin induces drug resistance more rapidly than cisplatin in H69 small cell lung cancer cells

Cancer Chemotherapy and Pharmacology

Volumn 58, Issue 2, 2006, Pages 256-265

  Stordal, Britta K ^a   Davey, Mary W ^b   Davey, Ross A ^a  

^a ROYAL NORTH SHORE HOSPITAL   (Australia)

^b UNIVERSITY OF TECHNOLOGY SYDNEY   (Australia)

Author keywords

Cellular response; Cisplatin; Drug resistance; Oxaliplatin; Regrowth resistance; Small cell lung cancer

Indexed keywords

BUTHIONINE SULFOXIMINE; CARBOPLATIN; CISPLATIN; COPPER SULFATE; DAUNORUBICIN; DOCETAXEL; EPIRUBICIN; ETOPOSIDE; GLUTATHIONE; IRINOTECAN; NAVELBINE; OXALIPLATIN; PACLITAXEL; SELENATE; VINBLASTINE;

ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER INHIBITION; CELL GROWTH; CELL LINE; CELL MODEL; CELL STRAIN; CELL STRAIN H69; CELL STRAIN H69CIS200; CELL STRAIN H69OX400; CELL SUBLINE; CELL SURVIVAL; CROSS RESISTANCE; CYTOTOXICITY; DRUG ACCUMULATION; DRUG DOSE ESCALATION; DRUG DOSE REGIMEN; DRUG EFFECT; DRUG INTERMITTENT THERAPY; DRUG RESISTANCE; DRUG RESPONSE; DRUG SENSITIVITY; HUMAN; HUMAN CELL; LUNG SMALL CELL CANCER; MODEL; PHENOTYPE; PRIORITY JOURNAL; REGROWTH RESISTANCE;

ANTINEOPLASTIC AGENTS; CARCINOMA, SMALL CELL; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; FLOW CYTOMETRY; HUMANS; LUNG NEOPLASMS; ORGANOPLATINUM COMPOUNDS;

EID: 33646481633     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-005-0148-7     Document Type: Article

References (56)

1. Thatcher N, Eckardt J, Green M (2003) Options for first- and second-line therapy in small cell lung cancer - a workshop discussion. Lung Cancer 41(Suppl 4):S37-S41
2. Rixe O, Ortuzar W, Alvarez M, Parker R, Reed E, Paull K, Fojo T (1996) Oxaliplatin, tetraplatin, cisplatin, carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 52:1855-1865
3. Ibrahim A, Hirschfeld S, Cohen MH, Griebel DJ, Williams GA, Pazdur R (2004) FDA drug approval summaries: oxaliplatin. Oncologist 9:8-12
4. Culy CR, Clemett D, Wiseman LR (2000) Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies. Drugs 60:895-924
5. Lenz G, Hacker UT, Kern W, Schalhorn A, Hiddemann W (2003) Adverse reactions to oxaliplatin: a retrospective study of 25 patients treated in one institution. Anticancer Drugs 14:731-733
6. Tisman G, MacDonald D, Shindell N, Reece E, Patel P, Honda N, Nishimora EK, Garris J, Shannahan W, Chisti N, McCarthy J, Nasser MS, Sargent D, Plant A (2004) Oxaliplatin toxicity masquerading as recurrent colon cancer. J Clin Oncol 22:3202-3204
7. Fojo T, Farrell N, Ortuzar W, Tanimura H, Weinstein J, Myers TG (2005) Identification of non-cross-resistant platinum compounds with novel cytotoxicity profiles using the NCI anticancer drug screen and clustered image map visualizations. Crit Rev Oncol Hematol 53:25-34
8. Tashiro T, Kawada Y, Sakurai Y, Kidani Y (1989) Antitumor activity of a new platinum complex, oxalato (trans-1-1,2-diaminocyclohexane)platinum (II): new experimental data. Biomed Pharmacother 43:251-260
9. Pendyala L, Creaven PJ (1993) In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 53:5970-5976
10. Kawai H, Kiura K, Tabata M, Yoshino T, Takata I, Hiraki A, Chikamori K, Ueoka H, Tanimoto M, Harada M (2002) Characterization of non-small-cell lung cancer cell lines established before and after chemotherapy. Lung Cancer 35:305-314
11. Kuroda H, Sugimoto T, Ueda K, Tsuchida S, Horii Y, Inazawa J, Sato K, Sawada T (1991) Different drug sensitivity in two neuroblastoma cell lines established from the same patient before and after chemotherapy. Int J Cancer 47:732-737
12. Kollmannsberger C, Beyer J, Liersch R, Schoeffski P, Metzner B, Hartmann JT, Rick O, Stengele K, Hohloch K, Spott C, Kanz L, Bokemeyer C (2004) Combination chemotherapy with gemcitabine plus oxaliplatin in patients with intensively pretreated or refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 22:108-114
13. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Skarlos D (2004) Gemcitabine and oxaliplatin (GEMOX) in patients with cisplatin-refractory germ cell tumors: a phase II study. Ann Oncol 15:493-497
14. Pectasides D, Pectasides M, Farmakis D, Aravantinos G, Nikolaou M, Koumpou M, Gaglia A, Kostopoulou V, Mylonakis N, Economopoulos T, Raptis SA (2004) Oxaliplatin and irinotecan plus granulocyte-colony stimulating factor as third-line treatment in relapsed or cisplatin-refractory germ-cell tumor patients: a phase II study. Eur Urol 46:216-221
15. Kollmannsberger C, Rick O, Derigs HG, Schleucher N, Schoffski P, Beyer J, Schoch R, Sayer HG, Gerl A, Kuczyk M, Spott C, Kanz L, Bokemeyer C (2002) Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: a study of the German Testicular Cancer Study Group. J Clin Oncol 20:2031-2037
16. Markman M, Hoskins W (1992) Responses to salvage chemotherapy in ovarian cancer: a critical need for precise definitions of the treated population [comment]. J Clin Oncol 10:513-514
17. Soulie P, Bensmaine A, Garrino C, Chollet P, Brain E, Fereres M, Jasmin C, Musset M, Misset JL, Cvitkovic E (1997) Oxaliplatin/cisplatin (L-OHP/CDDP) combination in heavily pretreated ovarian cancer. Eur J Cancer 33:1400-1406
18. Dieras V, Bougnoux P, Petit T, Chollet P, Beuzeboc P, Borel C, Husseini F, Goupil A, Kerbrat P, Misset JL, Bensmaine MA, Tabah-Fisch I, Pouillart P (2002) Multicentre phase II study of oxaliplatin as a single-agent in cisplatin/carboplatin +/- taxane-pretreated ovarian cancer patients. Ann Oncol 13:258-266
19. Chollet P, Bensmaine MA, Brienza S, Deloche C, Cure H, Caillet H, Cvitkovic E (1996) Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 7:1065-1070
20. Sockalingam R, Filippich L, Charles B, Murdoch B (2002) Cisplatin-induced ototoxicity and pharmacokinetics: preliminary findings in a dog model. Ann Otol Rhinol Laryngol 111:745-750
21. Liu J, Kraut E, Bender J, Brooks R, Balcerzak S, Grever M, Stanley H, D'Ambrosio S, Gibson-D'Ambrosio R, Chan KK (2002) Pharmacokinetics of oxaliplatin (NSC 266046) alone and in combination with paclitaxel in cancer patients. Cancer Chemother Pharmacol 49:367-374
22. Marks DC, Belov L, Davey MW, Davey RA, Kidman AD (1992) The MTT cell viability assay for cytotoxicity testing in multidrug-resistant human leukemic cells. Leuk Res 16:1165-1173
23. Suzukake K, Petro BJ, Vistica DT (1982) Reduction in glutathione content of L-PAM resistant L1210 cells confers drug sensitivity. Biochem Pharmacol 31:121-124
24. Grech KV, Davey RA, Davey MW (1998) The relationship between modulation of MDR and glutathione in MRP-overexpressing human leukemia cells. Biochem Pharmacol 55:1283-1289
25. Sandler AB (2003) Chemotherapy for small cell lung cancer. Semin Oncol 30:9-25
26. Hong WS, Saijo N, Sasaki Y, Minato K, Nakano H, Nakagawa K, Fujiwara Y, Nomura K, Twentyman PR (1988) Establishment and characterization of cisplatin-resistant sublines of human lung cancer cell lines. Int J Cancer 41:462-467
27. Twentyman PR, Wright KA, Rhodes T (1991) Radiation response of human lung cancer cells with inherent and acquired resistance to cisplatin. Int J Radiat Oncol Biol Phys 20:217-220
28. Locke VL, Davey RA, Davey MW (2003) Modulation of drug and radiation resistance in small cell lung cancer cells by paclitaxel. Anticancer Drugs 14:523-531
29. Hospers GA, Mulder NH, de Jong B, de Ley L, Uges DR, Fichtinger-Schepman AM, Scheper RJ, de Vries EG (1988) Characterization of a human small cell lung carcinoma cell line with acquired resistance to cis-diamminedichloroplatinum(II) in vitro. Cancer Res 48:6803-6807
30. Moritaka T, Kiura K, Ueoka H, Tabata M, Segawa Y, Shibayama T, Takigawa N, Ohnoshi T, Harada M (1998) Cisplatin-resistant human small cell lung cancer cell line shows collateral sensitivity to vinca alkaloids. Anticancer Res 18:927-933
31. Jain N, Lam YM, Pym J, Campling BG (1996) Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin. Cancer 77:1797-1808
32. Teicher BA, Holden SA, Herman TS, Sotomayor EA, Khandekar V, Rosbe KW, Brann TW, Korbut TT, Frei E III (1991) Characteristics of five human tumor cell lines and sublines resistant to cis-diamminedichloroplatinum(II). Int J Cancer 47:252-260
33. Savaraj N, Wu C, Wangpaichitr M, Kuo MT, Lampidis T, Robles C, Furst AJ, Feun L (2003) Overexpression of mutated MRP4 in cisplatin resistant small cell lung cancer cell line: collateral sensitivity to azidothymidine. Int J Oncol 23:173-179
34. Kuppen PJ, Schuitemaker H, van't Veer LJ, de Bruijn EA, van Oosterom AT, Schrier PI (1988) cis-diamminedichloroplatinum(II)-resistant sublines derived from two human ovarian tumor cell lines. Cancer Res 48:3355-3359
35. Belvedere G, Imperatori L, Damia G, Tagliabue G, Meijer C, de Vries EG, D'Incalci M (1996) In vitro and in vivo characterisation of low-resistant mouse reticulosarcoma (M5076) sublines obtained after pulse and continuous exposure to cisplatin. Eur J Cancer 32A:2011-2018
36. Poulain L, Lincet H, Duigou F, Deslandes E, Sichel F, Gauduchon P, Staedel C (1998) Acquisition of chemoresistance in a human ovarian carcinoma cell is linked to a defect in cell cycle control. Int J Cancer 78:454-463
37. Lai SL, Hwang J, Perng RP, Whang-Peng J (1995) Modulation of cisplatin resistance in acquired-resistant nonsmall cell lung cancer cells. Oncol Res 7:31-38
38. El Akawi Z, Abu-Hadid M, Perez R, Glavy J, Zdanowicz J, Creaven PJ, Pendyala L (1996) Altered glutathione metabolism in oxaliplatin resistant ovarian carcinoma cells. Cancer Lett 105:5-14
39. Mishima M, Samimi G, Kondo A, Lin X, Howell SB (2002) The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 38:1405-1412
40. Hector S, Bolanowska-Higdon W, Zdanowicz J, Hitt S, Pendyala L (2001) In vitro studies on the mechanisms of oxaliplatin resistance. Cancer Chemother Pharmacol 48:398-406
41. Rennicke A, Voigt W, Mueller T, Fruehauf A, Schmoll HJ, Beyer C, Dempke W (2005) Resistance mechanisms following cisplatin and oxaliplatin treatment of the human teratocarcinoma cell line 2102EP. Anticancer Res 25:1147-1155
42. Preisler HD, Gopal V (1994) Regrowth resistance in leukemia and lymphoma: the need for a new system to classify treatment failure and for new approaches to treatment. Leuk Res 18:149-160
43. Preisler HD (1995) Multidrug resistance is more than MDR1 activity. Leuk Res 19:429-431
44. Chaney SG, Campbell SL, Bassett E, Wu Y (2005) Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol 53:3-11
45. Woynarowski JM, Faivre S, Herzig MC, Arnett B, Chapman WG, Trevino AV, Raymond E, Chaney SG, Vaisman A, Varchenko M, Juniewicz PE (2000) Oxaliplatin-induced damage of cellular DNA. Mol Pharmacol 58:920-927
46. Woynarowski JM, Chapman WG, Napier C, Herzig MC, Juniewicz P (1998) Sequence- and region-specificity of oxaliplatin adducts in naked and cellular DNA. Mol Pharmacol 54:770-777
47. Song IS, Savaraj N, Siddik ZH, Liu P, Wei Y, Wu CJ, Kuo MT (2004) Role of human copper transporter Ctr1 in the transport of platinum-based antitumor agents in cisplatin-sensitive and cisplatin-resistant cells. Mol Cancer Ther 3:1543-1549
48. Christen RD, Jekunen AP, Jones JA, Thiebaut F, Shalinsky DR, Howell SB (1993) In vitro modulation of cisplatin accumulation in human ovarian carcinoma cells by pharmacologic alteration of microtubules. J Clin Invest 92:431-440
49. Jekunen AP, Christen RD, Shalinsky DR, Howell SB (1994) Synergistic interaction between cisplatin and taxol in human ovarian carcinoma cells in vitro. Br J Cancer 69:299-306
50. Johnson SW, Shen D, Pastan I, Gottesman MM, Hamilton TC (1996) Cross-resistance, cisplatin accumulation, and platinum-DNA adduct formation and removal in cisplatin-sensitive and - resistant human hepatoma cell lines. Exp Cell Res 226:133-139
51. Burns BS, Edin ML, Lester GE, Tuttle HG, Tuttle ME, Wani MC, Bos GD (2001) Selective drug resistant human osteosarcoma cell lines. Clin Orthop Relat Res 383:259-267
52. Yamamoto K, Kikuchi Y, Kudoh K, Nagata I (2000) Modulation of cisplatin sensitivity by taxol in cisplatin-sensitive and - resistant human ovarian carcinoma cell lines. J Cancer Res Clin Oncol 126:168-172
53. Abal M, Andreu JM, Barasoain I (2003) Taxanes: microtubule and centrosome targets, and cell cycle dependent mechanisms of action. Curr Cancer Drug Targets 3:193-203
54. Ohta S, Nishio K, Kubo S, Nishio M, Ohmori T, Takahashi T, Saijo N (1993) Characterisation of a vindesine-resistant human small-cell lung cancer cell line. Br J Cancer 68:74-79
55. Wang Z, Xie Y, Wang H (2005) Changes in surviving messenger RNA level during chemotherapy treatment in ovarian cancer cells. Cancer Biol Ther 4:716-719
56. Jansen BA, Brouwer J, Reedijk J (2002) Glutathione induces cellular resistance against cationic dinuclear platinum anticancer drugs. J Inorg Biochem 89:197-202